Continuous glucose monitoring for pancreatic cancer patients

Exploratory study of glycemic variability in the treatment course of pancreatic cancer patients using continuous glucose monitoring

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs042230142

Enrollment

Registered

2024-03-18

Start date

2024-03-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases scheduled for pancreatoduodenectomy for resectable pancreatic cancer.

Interventions

Using a continuous glucose monitoring device to monitor glycemic variability throughout the treatment process in cases of pancreatic cancer.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Cases diagnosed with resectable pancreatic cancer. (2) Cases scheduled for pancreatoduodenectomy. (3) The age at the time of consent acquisition is between 18 and 85 years. (4) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is 0 or 1. (5) Meets all the following conditions based on the latest preoperative test values within 30 days before registration: - White blood cell count: >=2,500/uL and =10/*10^4uL - AST (Aspartate Aminotransferase): <=100U/L - ALT (Alanine Aminotransferase): <=100U/L - Total bilirubin: <=2.0 mg/dL (or <=4.0 mg/dL for cases with biliary drainage due to jaundice) - Serum creatinine: <=1.5 mg/dL (6) Written consent for participation in the trial has been obtained from the patient.

Exclusion criteria

Exclusion criteria: (1) Cases undergoing pancreatic resection other than pancreatoduodenectomy (such as total pancreatectomy,distal pancreatectomy, central pancreatectomy, or local pancreatectomy). (2) Undergoing continuous glucose monitoring for diabetes. (3) Cases deemed unsuitable as subjects for this trial by the attending physician.

Design outcomes

Primary

Measure	Time frame
The glycemic variability levels measured during each period of the treatment course for pancreatic cancer patients: Glucose concentrations are measured every 15 minutes for up to 14 days in a single session. Measurements taken for three days or more per session are considered valid. (1) At registration (2) Post neoadjuvant therapy (3) Acute postoperative period (4) Discharge after surgery (5) During postoperative adjuvant therapy (6) After completion of postoperative adjuvant therapy	—

Measure

Time frame

The glycemic variability levels measured during each period of the treatment course for pancreatic cancer patients: Glucose concentrations are measured every 15 minutes for up to 14 days in a single session. Measurements taken for three days or more per session are considered valid. (1) At registration (2) Post neoadjuvant therapy (3) Acute postoperative period (4) Discharge after surgery (5) During postoperative adjuvant therapy (6) After completion of postoperative adjuvant therapy

—

Secondary

Measure	Time frame
(1) Association between glycemic variability and treatment adherence Presence of preoperative complications, impact on the initiation of NAC (Neoadjuvant Chemotherapy) Adherence to NAC Impact on the start of surgery Postoperative complications, impact on the initiation of adjuvant therapy after surgery Adherence to postoperative adjuvant therapy (2) Relationship between glycemic variability and clinical symptoms (weight changes, nutritional status[Alb, T-chol, Lymphocyte, PNI, NLR, PLR, CONUT)	—

Measure

Time frame

(1) Association between glycemic variability and treatment adherence Presence of preoperative complications, impact on the initiation of NAC (Neoadjuvant Chemotherapy) Adherence to NAC Impact on the start of surgery Postoperative complications, impact on the initiation of adjuvant therapy after surgery Adherence to postoperative adjuvant therapy (2) Relationship between glycemic variability and clinical symptoms (weight changes, nutritional status[Alb, T-chol, Lymphocyte, PNI, NLR, PLR, CONUT)

—

Contacts

Public ContactHidemasa Kubo

Shizuoka Cancer Center

h.kubo@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026